Autolus Therapeutics (NASDAQ:AUTL) Sets New 52-Week Low - Here's What Happened

Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report)'s stock price hit a new 52-week low during mid-day trading on Thursday . The company traded as low as $2.29 and last traded at $2.29, with a volume of 2277337 shares changing hands. The stock had previously closed at $2.49.

Analyst Ratings Changes

Several research firms have issued reports on AUTL. Redburn Atlantic upgraded Autolus Therapeutics from a "neutral" rating to a "buy" rating and set a $13.00 target price on the stock in a research note on Friday, November 15th. The Goldman Sachs Group upgraded shares of Autolus Therapeutics from a "neutral" rating to a "buy" rating and raised their price target for the company from $7.00 to $7.60 in a report on Monday, November 18th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research note on Thursday, December 5th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Autolus Therapeutics has a consensus rating of "Buy" and an average price target of $10.40.

Autolus Therapeutics Stock Down 2.2 %

The company has a market capitalization of $596.05 million, a PE ratio of -1.85 and a beta of 1.98. The business has a 50 day simple moving average of $3.48 and a 200 day simple moving average of $3.81.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same quarter in the previous year, the firm earned ($0.26) EPS. Equities analysts expect that Autolus Therapeutics plc will post -0.94 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Exchange Traded Concepts LLC lifted its holdings in shares of Autolus Therapeutics by 9.8% during the third quarter. Exchange Traded Concepts LLC now owns 41,866 shares of the company's stock worth $152,000 after purchasing an additional 3,740 shares during the period. Wealth Effects LLC lifted its stake in Autolus Therapeutics by 19.5% during the 2nd quarter. Wealth Effects LLC now owns 49,000 shares of the company's stock valued at $171,000 after acquiring an additional 8,000 shares during the period. Bellevue Group AG lifted its stake in Autolus Therapeutics by 27.7% during the 3rd quarter. Bellevue Group AG now owns 41,500 shares of the company's stock valued at $151,000 after acquiring an additional 9,000 shares during the period. State Street Corp boosted its holdings in shares of Autolus Therapeutics by 1.7% in the 3rd quarter. State Street Corp now owns 606,544 shares of the company's stock valued at $2,202,000 after acquiring an additional 10,401 shares during the last quarter. Finally, ProShare Advisors LLC acquired a new stake in shares of Autolus Therapeutics in the second quarter worth $43,000. Hedge funds and other institutional investors own 72.83% of the company's stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.